Medtronic (MDT) Competitors $90.02 +0.62 (+0.69%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$89.43 -0.59 (-0.66%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDT vs. DXCM, ISRG, ABT, JNJ, NVST, SYK, TMO, BSX, BDX, and EWShould you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include DexCom (DXCM), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Envista (NVST), Stryker (SYK), Thermo Fisher Scientific (TMO), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), and Edwards Lifesciences (EW). These companies are all part of the "medical" sector. Medtronic vs. Its Competitors DexCom Intuitive Surgical Abbott Laboratories Johnson & Johnson Envista Stryker Thermo Fisher Scientific Boston Scientific Becton, Dickinson and Company Edwards Lifesciences DexCom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership. Which has preferable earnings & valuation, DXCM or MDT? Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDexCom$4.03B8.11$576.20M$1.3462.22Medtronic$33.54B3.44$4.66B$3.6224.87 Do insiders & institutionals have more ownership in DXCM or MDT? 97.8% of DexCom shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 0.2% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, DXCM or MDT? DexCom has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Is DXCM or MDT more profitable? Medtronic has a net margin of 13.90% compared to DexCom's net margin of 12.90%. DexCom's return on equity of 30.05% beat Medtronic's return on equity.Company Net Margins Return on Equity Return on Assets DexCom12.90% 30.05% 10.00% Medtronic 13.90%14.54%7.83% Does the media prefer DXCM or MDT? In the previous week, Medtronic had 42 more articles in the media than DexCom. MarketBeat recorded 61 mentions for Medtronic and 19 mentions for DexCom. DexCom's average media sentiment score of 1.43 beat Medtronic's score of 1.17 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 15 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medtronic 44 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer DXCM or MDT? DexCom presently has a consensus target price of $98.50, suggesting a potential upside of 18.15%. Medtronic has a consensus target price of $97.47, suggesting a potential upside of 8.27%. Given DexCom's stronger consensus rating and higher possible upside, research analysts plainly believe DexCom is more favorable than Medtronic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95Medtronic 0 Sell rating(s) 9 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.63 SummaryDexCom beats Medtronic on 12 of the 17 factors compared between the two stocks. Get Medtronic News Delivered to You Automatically Sign up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDT vs. The Competition Export to ExcelMetricMedtronicMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$115.33B$10.47B$5.56B$20.64BDividend Yield3.16%2.09%5.06%3.72%P/E Ratio24.8717.1228.2627.83Price / Sales3.4429.95437.1042.25Price / Cash11.6022.5637.1222.32Price / Book2.393.668.044.57Net Income$4.66B$235.43M$3.19B$989.30M7 Day Performance1.72%1.27%3.62%0.20%1 Month Performance3.24%5.34%5.98%5.53%1 Year Performance15.48%-15.78%29.39%10.30% Medtronic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDTMedtronic4.6142 of 5 stars$90.02+0.7%$97.47+8.3%+15.5%$115.33B$33.54B24.8795,000Trending NewsAnalyst ForecastGap UpDXCMDexCom4.7819 of 5 stars$82.97+0.0%$98.50+18.7%-26.9%$32.60B$4.03B62.0410,300Positive NewsISRGIntuitive Surgical4.6774 of 5 stars$535.38-1.7%$588.95+10.0%+15.3%$191.89B$8.35B78.5015,638Positive NewsAnalyst ForecastABTAbbott Laboratories4.9542 of 5 stars$132.98-1.1%$142.61+7.2%+26.5%$231.63B$41.95B17.25114,000Trending NewsUpcoming EarningsAnalyst ForecastJNJJohnson & Johnson4.8126 of 5 stars$155.15-0.6%$170.88+10.1%+4.7%$373.38B$88.82B17.26138,100Trending NewsUpcoming EarningsAnalyst ForecastNVSTEnvista3.2771 of 5 stars$19.73-3.3%$20.23+2.6%+26.0%$3.35B$2.51B-3.0312,300Analyst ForecastSYKStryker4.7996 of 5 stars$390.80-1.1%$427.30+9.3%+14.7%$149.14B$22.60B52.8053,000Positive NewsAnalyst ForecastTMOThermo Fisher Scientific4.9932 of 5 stars$416.06-3.1%$604.05+45.2%-20.6%$157.25B$42.88B24.43125,000Trending NewsDividend AnnouncementAnalyst ForecastAnalyst RevisionBSXBoston Scientific4.6488 of 5 stars$103.37-0.9%$116.09+12.3%+32.8%$152.95B$16.75B75.4653,000Trending NewsBDXBecton, Dickinson and Company4.8162 of 5 stars$172.72-2.0%$219.22+26.9%-23.2%$49.55B$20.18B32.9974,000Positive NewsEWEdwards Lifesciences4.3825 of 5 stars$76.67-0.2%$80.20+4.6%-14.2%$44.97B$5.44B10.9515,800News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies DXCM Competitors ISRG Competitors ABT Competitors JNJ Competitors NVST Competitors SYK Competitors TMO Competitors BSX Competitors BDX Competitors EW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MDT) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medtronic PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Medtronic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.